Global RWE Oncology Market 

In 2023, the global RWE oncology market is expected to grow at a CAGR of 13.2% and reach US$ 720 million. Clinical trial data must include real-world information. For evaluating the safety and effectiveness of medical therapies, randomized controlled trials (RCTs) continue to be the gold standard. Clinical trials often lack real-world context and perspectives provided by RWE.